Research
Hormonal
Semaglutide (2.4 mg weekly) and Liraglutide (3.0 mg daily) are effective pharmacological adjuncts for obesity, producing significant weight loss (15% and 8-10% respectively) when combined with lifestyle interventions.
For patients with BMI ≥ 30 (or ≥ 25 with comorbidities) who do not achieve goals with lifestyle changes alone, consider GLP-1 analogues. Semaglutide 2.4mg weekly yields ~15% weight loss; Liraglutide 3mg daily yields ~8-10%. These are adjuncts to, not replacements for, behavioral therapy.
StrongSupportsVERY_HIGH confidence
Le semaglutide, administré hebdomadairement à la dose de 2,4 mg, permet une perte de poids de 15 % en moyenne par rapport au poids de départ après une année et demie... Le liraglutide est approuvé... à la posologie de 3 mg une fois par jour... permet... une perte de poids moyenne de 8 à 10 % par rapport au poids initial.
Why this rating
Cites high-impact RCTs (Wilding et al., N Engl J Med 2021; Pi-Sunyer et al., N Engl J Med 2015).
Source
Comment prendre en charge l’obésité au cabinet d’un médecin généraliste ?
Serpil Berkcan et al. · Archive ouverte UNIGE (University of Geneva) · 2022
narrative_reviewCited 1×
Read the paper More from this paper
- Therapeutic Patient Education (TPS) and motivational interviewing using the '5A' method (Assess, Advise, Agree, Assist, Arrange) are the foundational, first-line interventions for obesity management in primary care, superior to generic advice.Good
- Orlistat (60mg OTC or 120mg Rx) is a pharmacological option that reduces fat absorption but has significant gastrointestinal side effects (steatorrhea) that can be managed through patient education.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →